Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on January 6, 2012. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata references "Madrigal Pharmaceuticals, Inc.," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock.
- Shares Offered: 7,000,000 shares.
- Offering Price: $4.40 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,050,000 additional shares.
- Expected Net Proceeds: Approximately $28.6 million (excluding over-allotment exercise).
- Underwriter: Jefferies & Company, Inc. (as representative).
- Expected Closing Date: On or about January 11, 2012.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity. The transaction is expected to increase the company's cash position by approximately $28.6 million upon closing, subject to customary conditions.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary regarding future operational performance. The document includes standard legal disclaimers stating that representations and warranties in the Underwriting Agreement are for the benefit of the contracting parties and should not be relied upon by investors as characterizations of the company's actual state of facts. The closing of the offering is subject to the satisfaction of customary closing conditions.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected January 11, 2012).
- Confirm whether the underwriters exercise the over-allotment option for an additional 1,050,000 shares.
- Review the final prospectus supplement for updated use of proceeds and risk factors.
- Check subsequent filings for the actual net proceeds received after deducting all expenses.